ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

ResMed (RMD) is anticipated to report strong year-over-year earnings growth for the quarter ended June 2025, with consensus estimates at $2.46 EPS (+18.3%) on revenues of $1.32 billion (+8.2%). The company's +5.16% Zacks Earnings ESP, combined with a Zacks Rank #3 and a consistent history of beating EPS estimates in the past four quarters, suggests a high probability of surpassing consensus expectations in its upcoming report, expected around July 31.

Analysis

ResMed (RMD) is positioned for a strong upcoming earnings report for the quarter ending June 2025, with consensus estimates pointing to significant year-over-year growth. Wall Street anticipates revenues of $1.32 billion, an 8.2% increase, and earnings per share of $2.46, representing an 18.3% rise from the prior year. The sentiment surrounding this report is notably bullish, supported by several key indicators. The consensus EPS estimate has been revised upward by 0.47% in the last 30 days, and more recent analyst estimates have pushed the Zacks Earnings ESP (Expected Surprise Prediction) to a positive +5.16%. When combined with the stock's Zacks Rank #3 (Hold), this model suggests a high statistical probability—nearly 70% according to the research cited—of the company surpassing the consensus EPS estimate. This outlook is further reinforced by ResMed's consistent performance history, having beaten EPS estimates in each of the last four quarters. While these factors signal a likely earnings beat, the ultimate stock reaction will heavily depend on management's forward-looking guidance and discussion of business conditions during the earnings call.

Key Decisions for Investors

• Given the positive +5.16% Earnings ESP and a consistent history of earnings beats, investors might consider positioning for a potential upside surprise ahead of the July 31 report.
• The primary focus should be on the magnitude of the potential earnings beat and, more critically, on management's forward-looking guidance, as this will likely be the main driver of the stock's performance post-announcement.
• While indicators are favorable, the stock's Zacks Rank #3 (Hold) and the inherent uncertainty of earnings events warrant caution; an earnings beat does not guarantee a positive stock reaction if guidance or other factors disappoint.